Evaxion Biotech A/S announced on April 28, 2025, that 80% of targets in its EVX-01 vaccine successfully triggered a tumor-reactive immune response, presented at the AACR Annual meeting. This filing reflects positively on their clinical advancements in AI-powered vaccines.